Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Recruiting · NCT06233110 · Registry updated 2026-01-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 1 | 2026-01-22 | NCT06233110 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| National Institutes of Health (NIH) | 667 |
| Rigel Pharmaceuticals | 13 |
| Stefanie Sarantopoulos, MD, PhD. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke | Durham | United States | 4 |